Norman Biomed secured €300 million funding commitment to develop low-cost mRNA vaccines

Normax Biomed has secured a €300 million funding commitment to develop low-cost mRNA vaccines.

Dublin Airport Logistics Park was chosen to host the first of 100 vaccine factories the Irish-headquartered biotechnology company intends to develop.

Read the full article below.